Why the study?
Do alternative platelet function assays (VerifyNow, VASP, MEA, Impact-R) correlate with light transmission aggregometry to estimate clopidogrel-mediated platelet inhibition in patients on DAPT after elective PCI?
Population
80 patients on dual antiplatelet therapy after elective percutaneous intervention with stent implantation
Comparison
VerifyNow P2Y12 assay, vasodilator-stimulated… vs Light transmission aggregometry (LTA)
Design
Cross-sectional
Authors
Loading...
Assays' low sensitivity limits diagnostic use for clopidogrel response; leaves open prospective validation against clinical outcomes.
Do alternative platelet function assays (VerifyNow, VASP, MEA, Impact-R) correlate with light transmission aggregometry to estimate clopidogrel-mediated platelet inhibition in patients on DAPT after elective PCI?
Alternative platelet function assays correlate with LTA for assessing clopidogrel inhibition, but their low sensitivity and specificity limit their current clinical utility as diagnostic tests.
Steiner et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: